ATLANTA, June 3, 2019 /PRNewswire-PRWeb/ -- Genedata, a leading provider of enterprise software solutions for biopharmaceutical
Developed in close collaboration with partners across the biopharmaceutical industry, Genedata Expressionist provides unique workflow solutions addressing specific customer needs through out-of-the-box software functionalities. These solutions can be configured to automate complex MS data processing steps, enabling customers to scale up their experimental throughput.
The new release includes the following highlights:
Beyond streamlining workflows for characterization of biopharmaceuticals, Genedata Expressionist is increasingly being adopted to automate Host-Cell Protein (HCP) analysis due to its advanced built-in capabilities for proteomics analysis. As an instrument- and vendor-agnostic software platform, Genedata Expressionist continues to support the latest high-end MS instruments and thereby create new analytical solutions that address unmet needs. For this release, Genedata worked closely with Bruker to support their novel timsTOF Pro instrument; providing customers with a high-performance HCP and proteomics analytical system that offers unparalleled speed, scalability, and sensitivity.
By streamlining and automating complex MS data processing, analysis, and reporting workflows within and across laboratories, Genedata Expressionist empowers scientists to make informed decisions based on high-quality results.
"The latest release of Genedata Expressionist—an important component of our Genedata Biopharma Platform— reinforces our continued commitment to support the rapidly evolving needs of the biopharmaceutical industry, such as support of MAM. Genedata Expressionist enables our customers to efficiently scale up their internal data processing workflows, while at the same time improving result quality." commented Dr. Othmar Pfannes, CEO of Genedata. "Furthermore, we remain committed to partnering with leading technology providers such as Bruker to offer our joint customers new solutions to not only accelerate discovery, development, and commercialization of novel biopharmaceuticals, but ultimately also to reduce costs by streamlining and automating complex analytical processes."
Subscribe to our Free Newsletters!